FFAR2 and fatty liver disease: Consumption of SCFAs can alleviate hepatic steatosis by activating G protein-coupled receptors (GPR)41 and GPR43, which stimulate the release of the gut hormone peptide YY from enteroendocrine cells within the mucosa, ultimately reducing energy intake and mitigating the severity of hepatic steatosis [45].